[go: up one dir, main page]

PE20151431A1 - Formulaciones de lorazepam de liberacion controlada - Google Patents

Formulaciones de lorazepam de liberacion controlada

Info

Publication number
PE20151431A1
PE20151431A1 PE2015001249A PE2015001249A PE20151431A1 PE 20151431 A1 PE20151431 A1 PE 20151431A1 PE 2015001249 A PE2015001249 A PE 2015001249A PE 2015001249 A PE2015001249 A PE 2015001249A PE 20151431 A1 PE20151431 A1 PE 20151431A1
Authority
PE
Peru
Prior art keywords
lorazepam
release
controlled
controlled release
release lorazepam
Prior art date
Application number
PE2015001249A
Other languages
English (en)
Inventor
Douglas A Saltel
Michael Vachon
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151431(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of PE20151431A1 publication Critical patent/PE20151431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Referida a una composicion farmaceutica caracterizada porque comprende 0.5 a 10 mg de lorazepam en combinacion con excipientes farmaceuticamente aceptables suficientes para proporcionar una forma de dosificacion oral solida que tiene una liberacion controlada de lorazepam; la liberacion controlada de lorazepam es: (1) una liberacion sustancialmente de orden cero y (2) la liberacion del lorazepam alcanza 90% dentro del intervalo de tiempo de 7 a 12 horas; y los parametros de liberacion controlada se determinan en una prueba de disolucion farmaceutica que comprende solucion amortiguadora de pH 6.8
PE2015001249A 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberacion controlada PE20151431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08

Publications (1)

Publication Number Publication Date
PE20151431A1 true PE20151431A1 (es) 2015-09-23

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001249A PE20151431A1 (es) 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberacion controlada

Country Status (16)

Country Link
EP (1) EP2943186A1 (es)
JP (1) JP2016504391A (es)
KR (1) KR20150127037A (es)
CN (1) CN105188682A (es)
AU (1) AU2014205356A1 (es)
BR (1) BR112015016322A8 (es)
CA (1) CA2897313A1 (es)
CL (1) CL2015001921A1 (es)
HK (1) HK1213803A1 (es)
IL (1) IL239778A0 (es)
MX (1) MX2015008757A (es)
PE (1) PE20151431A1 (es)
PH (1) PH12015501533A1 (es)
RU (1) RU2015128914A (es)
SG (1) SG11201505352RA (es)
WO (1) WO2014110248A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008756A2 (pt) 2017-11-01 2020-10-13 Edgemont Pharmaceuticals, LLC Trust composições farmacêuticas orais de lorazepam resistentes a álcool

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (es) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
AU4064285A (en) * 1984-03-21 1985-10-11 American Home Products Corporation Sustained release pharmaceutical capsules
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
WO2003005951A2 (en) 2001-07-10 2003-01-23 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
KR100822519B1 (ko) * 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제

Also Published As

Publication number Publication date
CA2897313A1 (en) 2014-07-17
HK1213803A1 (zh) 2016-07-15
WO2014110248A1 (en) 2014-07-17
BR112015016322A8 (pt) 2018-01-23
BR112015016322A2 (pt) 2017-07-11
IL239778A0 (en) 2015-08-31
CL2015001921A1 (es) 2015-12-18
SG11201505352RA (en) 2015-08-28
PH12015501533A1 (en) 2015-10-05
KR20150127037A (ko) 2015-11-16
CN105188682A (zh) 2015-12-23
AU2014205356A1 (en) 2015-07-30
RU2015128914A (ru) 2017-02-14
MX2015008757A (es) 2016-02-05
EP2943186A1 (en) 2015-11-18
JP2016504391A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CL2016001424A1 (es) Composiciones de liberación retardada de lionaclotida
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX2020013116A (es) Sales y cristales novedosos.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BR112017027688A2 (pt) Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
MX394857B (es) Composicion farmaceutica para administracion oral que comprende enzalutamida.
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
PE20151431A1 (es) Formulaciones de lorazepam de liberacion controlada
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2015016679A (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.
AR081007A1 (es) Combinacion farmaceutica caracterizada porque comprende ibuprofeno y l-arginina
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
NI201900084A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
AR094391A1 (es) Formulaciones de lorazepam de liberación sostenida
MX378413B (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
NI201300142A (es) Composición farmacéutica para uso en inflamación y dolor.
AR115724A1 (es) Composición farmacéutica que contiene un péptido

Legal Events

Date Code Title Description
FD Application declared void or lapsed